Latest Breaking News On - Deciphera pharmaceuticals - Page 7 : comparemela.com

Kuehn Law Encourages UMBF, HTLF, TBNK, and DCPH Investors to Contact Law Firm

Kuehn Law Encourages UMBF, HTLF, TBNK, and DCPH Investors to Contact Law Firm
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJustin kuehnHope bancorp incHope bancorpDeciphera pharmaceuticalsTerritorial bancorp incCo ltdDeciphera pharmaceuticals incHeartland financialUnited states incFinancial corporationParticipation mattersGet involvedMerger litigation

Japan s Ono Pharma to buy U S drugmaker Deciphera for $2 4bn

OSAKA Ono Pharmaceutical plans to purchase an American cancer drug maker for $2.4 billion in its largest acquisition yet, seeking growth with new-drug…

United statesDeciphera pharmaceuticalsNasdaq listed deciphera pharmaceuticalsReaking news

Deciphera Pharmaceuticals (NASDAQ:DCPH) Sees Large Volume Increase

Deciphera Pharmaceuticals (NASDAQ:DCPH) Sees Large Volume Increase
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesJpmorgan chase coPanagora asset management incJefferies financial groupDeerfield management companylp seriesDeciphera pharmaceuticals incNews ratings for deciphera pharmaceuticals dailyDeutsche bankInstitutional investors weigh in on deciphera pharmaceuticalsDeciphera pharmaceuticals tradingDeciphera pharmaceuticalsGet free reportAsset managementForest capital managementDeciphera pharmaceuticals daily

12 Health Care Stocks Moving In Monday s Pre-Market Session - Addex Therapeutics (NASDAQ:ADXN), Akanda (NASDAQ:AKAN)

Biodexa pharmaceuticalsDeciphera pharmaceuticalsKoninklijke philipsNkgen biotechAddex therapeuticsCyclacel pharmaceuticalsMereo biopharma groupAvalo therapeutics

Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2 4 Billion

Deciphera Shareholders to Receive $25.60 per Share in Cash Deciphera’s Kinase Inhibitor Expertise and Established Commercialization Platform in Key Markets Will Reinforce ONO Pharmaceutical’s.

United statesHong kongUnited kingdomNew zealandGyo sagaraStevenl hoerterExchange commissionGreenberg traurigEuropean unionDeciphera pharmaceuticalsGoodwin procterJp morgan securitiesDeciphera pharmaceuticals incCo ltdGlobal specialty pharmaChief executive officer